Linda Fitzgerald, PharmD, BCPS

Clinical Pharmacist Specialist in Transplant
Adjunct Clinical Assistant Professor in Pharmacy
Rotation(s) Offered: Lung Transplant/Pulmonary Medicine

Biography

I am a solid organ transplant clinical pharmacist specialist. I primarily work with the lung transplant team and adult cystic fibrosis program but do rotate within the solid organ transplant pharmacy team. I am serving as the Team Lead for the Transplant Pharmacy team.

Pharmacy School Attended: University of Missouri-Kansas City (2004)

Other Training:

  • PGY1 Pharmacy: Hospital of the University of Pennsylvania, Philadelphia PA (2005)
  • PGY2 Critical Care/Transplant: Hospital of the University of Pennsylvania, Philadelphia PA (2006)

Areas of Interest

Immunosuppression, Anti-infective prophylaxis: cytomegalovirus and others, Cystic fibrosis: CFTR modulators drug-drug interactions, QI initiatives

Honors & Awards

Nominated for Transplant Center Employee of the Year –Michigan Medicine: 2015, 2018

Published Articles or Reviews

  • White S, Sakon C, Fitzgerald L, Kam C, McDade E, Wong A. Comparison of vancomycin pharmacokinetics in cystic fibrosis patients pre and post-lung transplant. Clin Med Insights Circ Respir Pulm Med2020 Jun 15. 
  • Hurst TE, Fitzgerald LJ, Chan KM, DeGeorge C, Patil P, Gianchandani R. Post-transplant diabetes mellitus (PTDM) in lung transplant recipients: prevalence and outcomes. Trends in Transplant2019 Jun
  • Bixby A, Fitzgerald L, Leek R, Mellinger J, Sharma P, Tischer S. Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients. Transpl Infect Dis2019 Jun; 21(3): e13078.
  • Shaikh SA, Fitzgerald L, Tischer S. Safety and efficacy of biologic agents for the management of inflammatory bowel disease after liver transplantation. Pharmacotherapy2017 Dec; 37(12): 1578-1585.
  • Belloli EA, Degtiar I, Wang X, Yanik GA, Stuckey LJ, Verleden SE, Kazerooni EA, Ross BD, Murray S, Galban CJ, Lama VN. Parametric response mapping as an imaging biomarker in lung transplant recipients. Am J Respir Crit Care Med2017 Apr 1; 195(7): 942-952.
  • Sagana RL, Wesorick DH, Bassin BS, Georgia TE, Seagull FJ, Stuckey LJ.Care of the Hospitalized Patient with Acute Exacerbation of COPD. Ann Arbor, MI: Quality Department, University of Michigan Health System, 2016.
  • Patel T, Eschenauer G, Stuckey L, Carver P. Antifungal prophylaxis in lung transplant recipients. Transplantation2016; Epub 4 Mar 2016.
  • Walker NM, Belloli EA, Stuckey L, Chan KM, Lin J, Lynch W, Chang A, Mazzoni SM, Fingar DC, Lama VN. Mechanistic target of rapamycin complex 1 (mTORC1) and m TORC2 as key signaling intermediates in mesenchymal cell activation. J Biol Chem2016; 291 (12): 6262-71.
  • Early C, Stuckey L, Tischer S. Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options. Osteoporosis Int2015; Epub 16 Oct 2015.
  • Fitzgerald LJ, McMurry KA, Jia S, Combs MP, Lyu DM, Chan KM. Evaluation of targeted basiliximab induction therapy in lung transplant.J Heart Lung Transplant2020; 39(4): S323.
  • McMurry KA, Fitzgerald LJ, Lyu DM, Chan KM, Jia S. Conversion from tacrolimus IR (twice daily) orcyclosporine to tacrolimus XR (Envarsus®, once daily) in lung transplant recipients. J Heart Lung Transplant2020; 39(4): S505.
  • Lipp M, Crass R, Fitzgerald L, Patel T, Jia S. Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium versus tobramycin. Pediatr Pulmonol2019;54(s2):S375.
  • Linder KA, Patel TS, Kauffman CA, Fitzgerald LJ, Miceli MH. Evaluation of targeted vs. universal antifungal prophylaxis for invasive fungal infections after lung transplant. Open Forum Infect Dis2019Oct;6(Suppl 2): S636.
  • Bixby AL, Fitzgerald L, Cotiguala L, Park JM, Kaul D, Sonnenday C, Tischer S. Comparison of two dosing regimens of valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Am J Transplant2019;19(s3):721.
  • Crass R, Jia S, Patel TS, Fitzgerald L, SimonR, Pai M. Higher risk of acute kidney injury with piperacillin/tazobactam versus cefepime or meropenem in adult cystic fibrosis patients treated with vancomycin and tobramycin. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2019.
  • Belloli EA,FitzgeraldL, Lyu D, Moussa O,Chan K. Presence of de novo donor-specific antibodies to HLA-DQ in lung transplant recipients predicts poor survival. J Heart Lung Transplant2018; 37(4): S434-444.
  • Sagana RL,Stuckey LJ, Berry J, Collins H, Heinle A, Roaden L, Stepka D, Chang A, LinJ, Chan KM. Lung transplant recipient survival following urgent inpatient candidacy evaluation. J Heart Lung Transplant2016; 35(4): S228.
  • Stuckey LJ, Clark AM, Chang SJ, Chan KM, Bartos CE, Ojo TC. The effect of dornase alfa (rhDNase) on recurrent gram negative infections in adult cystic fibrosis lung transplant recipients. J Heart Lung Transplant2015; 35(4): S240.